Dig­i­tal health start­up Ro’s CEO talks GLP-1 drug pric­ing, short­ages and com­pound­ed shots

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

The fight to dom­i­nate the mar­ket for weight loss shots has nev­er been hot­ter, but drug­mak­ers still can’t make enough of the drugs to meet over­whelm­ing de­mand. Now new com­peti­tors like Am­gen are wad­ing in­to the are­na.

End­points News spoke with Ro CEO Zachari­ah Re­i­tano af­ter Eli Lil­ly and No­vo Nordisk re­port­ed first-quar­ter earn­ings this week to dis­cuss the phar­ma gi­ants’ di­verg­ing strate­gies to win cus­tomers, Lil­ly’s push in­to tele­health, and how Ro is nav­i­gat­ing per­sis­tent sup­ply short­ages. The dig­i­tal health start­up, val­ued at $7 bil­lion when it last raised mon­ey in 2022, is a ma­jor play­er in the mar­ket for on­line an­ti-obe­si­ty pre­scrip­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER